Bristol-Myers Squibb, AstraZeneca enter $1 billion diabetes pact

Share this article:
Bristol-Myers Squibb and AstraZeneca announced a collaboration deal worth $1 billion to develop and commercialize two investigational compounds for Type 2 diabetes. The compounds are saxagliptin, a dipeptidyl peptidase-4 inhibitor currently in Phase III development, and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor currently in Phase IIb development. Both compounds were discovered by Bristol-Myers Squibb. Terms of the deal include an upfront payment of $100 million by AstraZeneca to Bristol-Myers Squibb. BMS may also receive additional payments of up to $650 million based on development and regulatory milestones for the two compounds. Additional sales milestones up to $300 million per product are also possible.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.